Catalog No.
Product Name
Application
Product Information
Citations
-
IRAK-4 Inhibitor
IRAK-4 protein kinase inhibitor 2 selectively targets interleukin-1 receptor-associated kinase-4 (IRAK-4) with an IC50 of 4 μM. This inhibitor is instrumental in studying inflammatory and immune-related diseases, offering valuable insights into the mechanisms underlying these conditions. Its effective application in research may lead to better understanding and potential therapeutic developments in immune responses. -
IRAK4 Inhibitor
HS271 is a selective inhibitor of IRAK4, demonstrating potent activity with an IC50 of 7.2 μM. This compound exhibits superior enzymatic and cellular efficacy, making it suitable for studies investigating IRAK4-mediated signaling pathways. HS271’s excellent pharmacokinetic properties further enhance its utility in various biological research applications focused on inflammatory processes and immune response modulation. -
IRAK4 Inhibitor
GNE-2256 is a potent inhibitor of IRAK4 (Interleukin 1 receptor associated kinase 4) with a Ki of 1.4 nM, demonstrating high selectivity for this target. It effectively reduces IL-6 production with an IC50 of 190 nM, making it a valuable tool for investigating inflammatory responses and signaling pathways. GNE-2256 is suitable for studies involving autoimmune diseases and other conditions related to aberrant IL-6 signaling. -
IRAK Inhibitor
IRAK inhibitor 4 (trans) is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). This compound has demonstrated significant efficacy in blocking IRAK4 activation, thereby modulating the downstream signaling pathways involved in inflammatory responses. It is widely used in research applications focusing on inflammatory disorders and signaling pathways associated with innate immunity. -
IRAK4 Inhibitor
IRAK4-IN-8 is a potent inhibitor of IRAK4, an essential kinase in the interleukin-1 receptor (IL-1R) and Toll-like receptor (TLR) signaling pathways. By selectively inhibiting IRAK4, it modulates downstream inflammatory responses, making it a valuable tool for studying immune pathways. Its primary applications include research on autoimmune disorders, cancer immunotherapy, and the development of novel anti-inflammatory drugs. -
IRAK4 Inhibitor
IRAK4-IN-18 is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), exhibiting an IC50 value of 15 nM. This compound is effective in inhibiting lipopolysaccharide (LPS)-induced interleukin-23 (IL-23) production in THP-1 and dendritic cells, demonstrating its potential to modulate inflammatory responses. IRAK4-IN-18 is applicable for research into arthritis and related inflammatory diseases. -
IRAK1/4/pan-FLT3 Inhibitor
IRAK1/4/pan-FLT3 Kinase-IN-2 is a dual inhibitor targeting IRAK1, IRAK4, and FLT3 with IC50 values of 10 nM, 0.7 nM, and <0.5 nM, respectively. This compound demonstrates significant biological activity by extending survival in acute myeloid leukemia model mice. It serves as a valuable tool for research in hematological malignancies and associated therapeutic pathways, facilitating studies on the modulation of kinase activity in cancer. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-5 is a Cereblon-based targeted protein degrader specifically designed to induce the degradation of IRAK4. By modulating the ubiquitin-proteasome system, it enhances protein turnover, leading to a decrease in IRAK4 levels. This compound is valuable for research applications focused on inflammation and immune response regulation, enabling the investigation of IRAK4's role in various disease models. -
IRAK4 Inhibitor
IRAK4-IN-16 is a potent inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), displaying an IC50 value of 2.5 nM. This compound demonstrates significant cytotoxic effects against various lymphoma cell lines, including OCI-LY10, TMD8, Ramos, and HT, with respective IC50 values of 0.2 μM, 0.2 μM, 0.6 μM, and 2.7 μM. IRAK4-IN-16 is valuable for research in the mechanisms of inflammation and cancer therapy, particularly in targeting IRAK4-related pathways. -
Ligand for Target Protein for PROTAC
PROTAC IRAK4 ligand-4 is a selective ligand that targets IRAK4, facilitating the degradation of this protein via the PROTAC (proteolysis-targeting chimera) mechanism. This compound exhibits antitumor activity, making it a valuable tool for cancer research. Additionally, it can be utilized to synthesize the PROTAC IRAK4 degrader-12, contributing to the development of targeted therapeutic strategies in oncology. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 degrader-12 is a PROTAC compound designed to selectively target and induce the degradation of IRAK4 via the Cereblon E3 ligase pathway. It demonstrates a significant degradation efficacy, achieving a maximum degradation rate of 108.46% in K562 cells with an IC50 of 4.87 nM. This reagent is particularly useful for research applications focused on inflammatory signaling pathways and therapeutic development targeting IRAK4-related diseases. -
IRAK4 Inhibitor
IRAK4-IN-9 is a potent inhibitor of IRAK4, demonstrating an IC50 of 1.5 nM. This compound effectively disrupts MyD88-dependent signaling pathways, making it a valuable tool for investigating mechanisms of inflammation and immune response. IRAK4-IN-9 is relevant for research applications in inflammatory diseases, autoimmune disorders, and cancer biology. -
IRAK4 Inhibitor
IRAK4-IN-10 is a potent inhibitor of IRAK4, exhibiting an IC50 value of 1.5 nM. This compound effectively interrupts MyD88-dependent signaling pathways, making it a valuable tool for studying the molecular mechanisms underlying inflammatory and autoimmune diseases, as well as various cancers. Its ability to target IRAK4 positions IRAK4-IN-10 as a promising reagent for research in related therapeutic fields. -
IRAK4 Inhibitor
IRAK4-IN-13 is a potent and selective inhibitor of IRAK4 with an IC50 of 0.6 nM. This compound demonstrates significant metabolic clearance, with an intrinsic clearance rate of 96 µL/min/mg in human liver microsomes. IRAK4-IN-13 is useful for studying IRAK4-mediated signaling pathways and evaluating therapeutic strategies in various inflammatory diseases. -
IRAK4 Inhibitor
IRAK4-IN-31 is a selective inhibitor of IRAK4, a key kinase in the Toll-like receptor signaling pathway. This compound exhibits potent inhibitory activity against IRAK4, making it valuable for studying immune signaling and associated pathways. IRAK4-IN-31 is particularly relevant in research related to myelodysplastic syndromes (MDS) and may aid in elucidating therapeutic strategies for hematological malignancies. -
IRAK4 Modulator
IRAK4 modulator-1 is a selective modulator of IRAK4, demonstrating an IC50 of 4.647 μM. This compound is instrumental in the exploration of IRAK-mediated signaling pathways, making it a valuable tool for investigating diseases associated with dysregulated inflammation and immune responses. Researchers can utilize IRAK4 modulator-1 to further understand the role of IRAK4 in various pathological conditions. -
IRAK3 PROTAC Degrader
PROTAC IRAK3 degrader-2 is a potent IRAK3 PROTAC degrader with a DC50 of less than or equal to 50 nM. This compound promotes the ubiquitination and subsequent degradation of the IRAK3 protein, making it a valuable tool for studying immune-related diseases. Its unique design incorporates ligands for E3 ligase and a linker configuration, facilitating targeted degradation and aiding research into therapeutic strategies for modulating immune responses. -
IRAK4 Inhibitor
DW18134 is a selective inhibitor of interleukin receptor-associated kinase 4 (IRAK4) with an IC50 of 11.2 nM. It effectively inhibits the phosphorylation of IRAK4 and IKK, leading to downregulated secretion of pro-inflammatory cytokines TNF-α and IL-6. In preclinical studies, DW18134 demonstrates efficacy in mitigating lipopolysaccharide-induced peritonitis and dextran sulfate sodium-induced colitis in mouse models, while also preserving intestinal barrier integrity. This compound is valuable for researching inflammatory pathways and therapeutic strategies in inflammatory bowel disease. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-2 is a PROTAC-based compound designed to target and degrade IRAK4, displaying potent degradation efficacy with a DC50 value of 151 nM in peripheral blood mononuclear cells (PBMCs). It effectively reduces IRAK4 protein levels, achieving a DC50 of 36 nM in these cells. Additionally, PROTAC IRAK4 Degrader-2 inhibits the production of multiple cytokines, making it a valuable tool for research in inflammation and immune response modulation. -
PROTAC IRAK4 Degrader
KTX-612 is an orally bioavailable IRAK4 PROTAC degrader with a DC50 value of 7 nM. This compound is designed to selectively target and promote the degradation of IRAK4, a key protein involved in inflammatory and oncogenic signaling pathways. KTX-612 has potential applications in oncology research, facilitating studies focused on the modulation of IRAK4 and its implications in cancer progression and treatment. -
IRAK4 ligand
IRAK4 ligand-13 is a selective ligand targeting IRAK4, a key component in the interleukin-1 receptor and Toll-like receptor signaling pathways. This compound is designed for the development of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation. It is suitable for research applications aimed at modulating immune responses and studying signaling pathways associated with inflammation and cancer. -
IRAK4 Inhibitor
BIO-8169 is a selective inhibitor of interleukin receptor-associated kinase 4 (IRAK4) with an IC50 of 0.23 nM. This compound demonstrates significant anti-inflammatory activity by reducing the production of pro-inflammatory cytokines. Additionally, BIO-8169 shows promising pharmacokinetic properties, including effective blood-brain barrier penetration, indicated by a rat Kpu,u of 0.7, making it suitable for investigating autoimmune conditions such as experimental autoimmune encephalomyelitis (EAE). -
IRAK3 Degrader PROTAC
PROTAC IRAK3 degrader-1 is a potent and selective degrader targeting IRAK3, with an IC50 of 5 nM. This compound effectively facilitates the ubiquitination and subsequent degradation of IRAK3, thereby modulating inflammatory responses. Its primary research applications include studies on innate immunity and the development of targeted therapies for inflammatory diseases. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 degrader-4 is a Cereblon-based bifunctional molecule designed to degrade interleukin-1 receptor-associated kinase 4 (IRAK4). This compound facilitates targeted protein degradation, leading to effective modulation of IRAK4 levels in cells. Research applications include investigating inflammatory signaling pathways and therapeutic approaches for autoimmune diseases. -
PROTAC IRAK4 Degrader
KTX-497 is a potent IRAK4 degrader utilizing the PROTAC technology, exhibiting a DC50 value of 3 nM. This compound effectively targets and degrades IRAK4, making it a valuable tool for oncology research. Its mechanism allows for the selective modulation of signaling pathways implicated in cancer progression, facilitating the exploration of novel therapeutic strategies. -
PROTAC IRAK4 Degrader
KTX-955 is a potent IRAK4 degrader that facilitates the targeted degradation of IRAK4 protein. With DC50 values of 5 nM for IRAK4 and 130 nM for Ikaros, this compound demonstrates significant efficacy in modulating signaling pathways involved in tumorigenesis. KTX-955 comprises a CRBN ligand derived from Pomalidomide and a specific ligand targeting IRAK4, making it a valuable tool for research into cancer biology and therapeutic interventions. -
IRAK4 Inhibitor
IRAK4-IN-28 is a potent inhibitor of IRAK4, exhibiting an IC50 of 8.9 nM and a binding affinity characterized by a Kd of 0.58 nM. This compound is suitable for studies targeting inflammation and autoimmune diseases, providing valuable insights into the mechanisms of immune response modulation. Its selectivity and potency make it a useful tool for elucidating the role of IRAK4 in various biological processes. -
IRAK4 Inhibitor
IRAK4-IN-15 is a selective inhibitor of IRAK4, demonstrating a remarkable IC50 of 0.002 µM. This compound exhibits favorable pharmacokinetic predictions in humans with low intrinsic clearance. In vitro studies reveal its potent synergistic activity against MyD88/CD79 double mutant ABC-DLBCL, particularly when used in combination with Acalabrutinib, positioning IRAK4-IN-15 as a valuable tool in cancer research. -
IRAK4 Inhibitor
IRAK4-IN-30 is a potent inhibitor of IRAK4, with an IC50 of 0.6 nM. This compound effectively modulates the signaling pathways associated with the innate immune response. It is valuable for research applications focused on inflammation, autoimmunity, and cancer, providing insights into the mechanistic roles of IRAK4 in various biological processes. -
IRAK4 Inhibitor
IRAK4-IN-17 is a potent inhibitor of IRAK4, exhibiting an IC50 of 1.3 nM. This compound is instrumental for research involving diffuse large B-cell lymphoma (DLBCL), providing insight into the role of IRAK4 in oncogenic signaling pathways. Its high specificity and efficacy make it a valuable tool for investigating therapeutic strategies targeting IRAK4-related mechanisms in cancer biology. -
IRAK4 Inhibitor
ND-2158 is a competitive inhibitor of IRAK4, exhibiting a Ki value of 1.3 nM. This compound effectively suppresses LPS-induced TNF production in human white blood cells and demonstrates therapeutic potential by alleviating collagen-induced arthritis and preventing gout formation in mouse models. Additionally, ND-2158 shows antitumor activity in vivo, making it a valuable tool for research in inflammation and cancer biology. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-10 is a potent IRAK4 degrader that utilizes a Cereblon ligand to initiate targeted protein degradation. It demonstrates remarkable biological activity, achieving a maximum degradation of 95.94% with a DC50 value of 7.68 nM in HEK293 cells. This compound is essential for research applications focused on inflammatory signaling pathways and therapeutic strategies targeting IRAK4. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-6 is a Cereblon-based PROTAC designed to selectively degrade interleukin-1 receptor-associated kinase 4 (IRAK4). This compound targets IRAK4 for ubiquitination and subsequent proteasomal degradation, effectively modulating inflammatory signaling pathways. It is utilized in research applications focused on understanding the role of IRAK4 in immune responses and developing novel therapeutic strategies for inflammatory diseases. -
IRAK4 Inhibitor
IRAK4-IN-11 is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), demonstrating a potent inhibition profile with an IC50 of 0.008 µM. This compound effectively suppresses phosphorylated IRAK4 with an IC50 of 0.19 µM, making it a valuable tool for studying the IL-1 signaling pathway. IRAK4-IN-11 is suitable for research applications focused on inflammation, immune response, and related therapeutic areas. -
IRAK4 Inhibitor
IRAK4-IN-19 is a potent inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with an IC50 value of 4.3 nM. This compound effectively inhibits lipopolysaccharide (LPS)-induced IL-23 production in THP-1 and dendritic cells, demonstrating its ability to influence inflammatory pathways. IRAK4-IN-19 is valuable for research focused on arthritis and other inflammatory diseases, as it has shown efficacy in preventing the development of arthritis in animal models. -
IRAK4 Type II Inhibitor
HG-12-6 is a type II inhibitor of IRAK4, exhibiting preferential binding to unphosphorylated inactive IRAK4 with an IC50 of 165 nM. This compound effectively modulates IRAK4 activity, making it a valuable tool for studying its role in autoimmunity and inflammation. Researchers can utilize HG-12-6 to investigate pathways associated with immune responses and inflammatory disorders. -
IRAK Inhibitor
IRAK4-IN-25 is a potent inhibitor of IRAK4, with an IC50 of 7.3 nM, demonstrating significant oral bioavailability and low clearance (Cl=12 mL/min/kg). This compound effectively inhibits the production of pro-inflammatory cytokines, making it a valuable tool for studying inflammatory and autoimmune disorders. Its in vitro safety and ADME profiles further support its potential applications in research aimed at understanding immune response modulation. -
Ligand for IRAK4
IRAK4 ligand-14 is a selective ligand for the interleukin-1 receptor-associated kinase 4 (IRAK4). This compound can facilitate the synthesis of proteolysis-targeting chimeras (PROTACs), including APH02174. Its application in research primarily focuses on elucidating the role of IRAK4 in immune signaling pathways and developing innovative therapeutic strategies targeting IRAK4-related diseases. -
IRAK4 Inhibitor
IRAK4-IN-24 is a potent inhibitor of IRAK4, a key kinase involved in the signaling pathways of inflammatory responses. This compound demonstrates significant biological activity, particularly in models of inflammatory and autoimmune disorders. IRAK4-IN-24 facilitates research into the modulation of immune responses and provides insights into potential therapeutic strategies targeting IRAK4 in various disease contexts. -
IRAK4 Inhibitor
IRAK4-IN-26 is a potent inhibitor of IRAK4 with an IC50 of 6.2 nM. This compound exhibits an oral bioavailability of 21%, making it suitable for in vivo studies. IRAK4-IN-26 is valuable for research into inflammatory and autoimmune disorders, facilitating the exploration of therapeutic strategies targeting IRAK4 signaling pathways. -
IRAK4 Inhibitor
BMS-978299 is a selective inhibitor of IRAK4, a critical kinase in the Toll-like receptor (TLR) signaling pathway. This compound demonstrates potent activity in modulating immune response and inflammation, making it a valuable tool for investigating immune disorders and related therapeutic interventions. Researchers can utilize BMS-978299 to further understand the role of IRAK4 in various pathophysiological conditions and to explore potential treatment strategies for immune-related diseases. -
IRAK4 Inhibitor
IRAK4-IN-34 is a potent and selective inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4), exhibiting an IC50 of 0.73 nM. This compound demonstrates significant selectivity against hERG and other kinase targets. With favorable pharmacokinetic properties for in vivo applications, IRAK4-IN-34 is valuable for research into inflammatory diseases and related pathways. -
IRAK4 Inhibitor
ND-2110 is a selective inhibitor of IRAK4, exhibiting a binding affinity with a Ki of 7.5 nM. It effectively targets the ATP binding site of IRAK4 and demonstrates significant biological activity in activated B cell-like (ABC) subtype diffuse large B cell lymphoma (DLBCL) cell lines harboring MYD88 L265P mutations. ND-2110 has been shown to inhibit LPS-induced TNF production and demonstrates therapeutic potential in mouse models of collagen-induced arthritis and gout. -
Src
Canine Secretin is an endocrine hormone that primarily targets the Src kinase pathway. It stimulates the secretion of bicarbonate-rich pancreatic fluids and regulates gastric chief cell function, as well as paracellular permeability in canine gastric monolayers. This reagent is valuable for research applications involving gastrointestinal physiology and pancreatic function in canines. -
EphB4/Src Kinase Inhibitor
AZ12672857 is a potent inhibitor of EphB4 and Src kinases, demonstrating an IC50 of 1.3 nM for EphB4. This compound significantly inhibits the proliferation of c-Src transfected 3T3 cells with an IC50 of 2 nM and autophosphorylation of EphB4 in CHO-K1 cells with an IC50 of 9 nM. AZ12672857 can be utilized in studies investigating signaling pathways related to cancer and cell growth regulation. -
EGFR Inhibitor
Afatinib N-Oxide is an oxidative degradation product of Afatinib dimaleate, an irreversible inhibitor of the epidermal growth factor receptor (EGFR) family. This compound serves as a valuable tool for characterizing the stability and degradation pathways of Afatinib in chemical research. It may also aid in understanding the mechanistic effects of EGFR inhibition in various biological contexts. -
HPK1 Inhibitor
HPK1-IN-7 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1, MAP4K1) with an IC50 of 2.6 nM, demonstrating excellent selectivity among kinases. It exhibits some selectivity against IRAK4 and GLK, with IC50 values of 59 nM and 140 nM, respectively. This compound has shown significant efficacy in the MC38 syngeneic tumor model, particularly when used in combination with anti-PD1 therapy, highlighting its potential in immuno-oncology research. -
Endogenous Metabolite
PF-05387252 is a potent and selective inhibitor of IRAK4, effectively targeting endogenous Toll-like receptor (TLR) signaling pathways. This compound exhibits significant anti-inflammatory activity in experimental models, suggesting potential therapeutic applications in conditions such as psoriasis. While PF-05387252 has demonstrated efficacy in reducing inflammation in animal studies, its effectiveness in clinical settings for psoriasis has yet to be established. -
Endogenous Metabolite
IRAK4-IN-29 is a selective inhibitor of the interleukin-1 receptor-associated kinase 4 (IRAK4), demonstrating low nanomolar activity. This compound effectively disrupts TLR-mediated signaling pathways and exhibits significant inhibition of cytokine production in response to LPS and R848 stimulation. In vivo studies reveal that IRAK4-IN-29 can suppress LPS-induced TNFα, mirroring the phenotype observed in IRAK4 gene-deficient mice. Furthermore, IRAK4-IN-29 possesses favorable medicinal chemistry characteristics, including microsomal stability and solubility, indicating its potential for clinical applications in inflammatory diseases. -
PROTAC Linker
3,9-Dimethyl-3,9-diazaspiro[5.5]undecane is a rigid linker designed for use in the synthesis of PROTACs (Proteolysis Targeting Chimeras). This compound facilitates targeted protein degradation, exemplified by its application in creating potent IRAK4 PROTAC degraders, such as FIP22, which demonstrate efficacy in conditions like atopic dermatitis. Its structural characteristics enhance the stability and specificity of PROTAC development, making it a valuable tool in chemical biology research.
